OpenEvidence, which facilitates access to medical information through artificial intelligence, has raised $250 million in a Series D investment round led by Thrive Capital and DST Global. This investment increases the company's market value to $12 billion.
According to information dated January 22, 2026, the current investors of OpenEvidence, which has received a total of $700 million in investments so far, include prestigious institutions such as Sequoia Capital, Nvidia, Kleiner Perkins, Blackstone, Bond, Craft Ventures and Mayo Clinic.
OpenEvidence attracts attention with its artificial intelligence-based search and information platform for doctors. The platform is used as a tool to support decision-making in daily medical practice by providing doctors with fast and accurate clinical answers based on high-quality data collected from clinical guidelines, medical literature and peer-reviewed scientific journals.
The company's CEO Daniel Nadler said that OpenEvidence gains a competitive advantage thanks to its approach based on both data quality and real clinical usage data. The platform is currently used regularly by physicians at more than 10,000 hospitals and medical centers in the United States and has supported more than 18 million clinical consultations as of December 2025.
The startup aims to expand its research and development (R&D) activities and further improve the platform's capabilities with the new investment.
